Fig. 2.

Percentage of a Ki67⁺CD4⁺, b Ki67⁺CD8⁺, c HLA-DR⁺CD4⁺ and d HLA-DR⁺CD8⁺ cells at baseline, during and after therapy. Lenalidomide was administered on weeks 1–16 and alemtuzumab weeks 5–16. * p < 0.05, ** p < 0.01, *** p < 0.001